ArticleMolecular biomedicine2025
Iron accumulation in hypothalamus promotes age-dependent obesity and metabolic dysfunction of male mice.
Article in Molecular biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Early-Life High-Fat Diet Impairs Autophagy and Reduces GABANutrients · 2026Article
- Organ-Specific Regulation of Systemic Aging: Focus on the Brain, Skeletal Muscle, and Gut.Cells · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
With the progression of aging, age-dependent obesity and metabolic disorders have garnered increasing attention, yet their underlying mechanisms remain poorly understood. Dysregulation of iron homeostasis is strongly linked to aging; however, its role in age-dependent obesity remains unclear. As the hypothalamus, a key regulator of energy homeostasis, plays a pivotal role in metabolic regulation during aging, we investigated whether hypothalamic iron accumulation contributes to age-dependent obesity. We first observed elevated iron levels in the hypothalamus of aged mice, particularly in the arcuate nucleus. To test whether reducing iron could mitigate obesity, we intranasally administered the iron chelator deferiprone to aged mice and found that it effectively lowered hypothalamic iron levels and ameliorated metabolic function. Using a ferric ammonium citrate-induced iron overload cell model, we discovered that excess iron triggers mitochondrial dysfunction and oxidative stress, leading to ROS-dependent nuclear translocation of forkhead box protein O1 (FoxO1) and subsequent upregulation of AgRP expression. To confirm this mechanism in vivo, we generated agouti-related peptide (AgRP) neuron-specific transferrin receptor 1(Tfrc) knockout mice and found that reducing iron uptake in these neurons decreased ROS levels, inhibited FoxO1 nuclear translocation, and suppressed AgRP neuronal activity in aged mice. This intervention ultimately protected against age-related obesity and metabolic dysfunction. Our study identifies a critical iron accumulation-ROS-FoxO1-AgRP signaling axis in hypothalamic neurons as a key driver of age-dependent obesity. This study elucidates the broader implications of iron homeostasis dysregulation in aging-associated pathologies and offers novel perspectives for investigating age-dependent obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.